drugset / Trial / NCT01020331

Memantine Therapy in Amyotrophic Lateral Sclerosis

NCT01020331

RandomizedSingle-groupOpen-labelTreatment

Summary

Tau, a protein in the cerebrospinal fluid CSF is believed to be elevated in amyotrophic lateral sclerosis (ALS) patients. The investigators believe that Tau is truly a marker of increased neuronal death from any disease process. It is been shown that Memantine can inhibit and reverse the abnormal hyperphosphorylation of Tau and therefore the investigators are looking at the efficacy of Memantine at 10 mg twice a day (BID) to see if disease progression correlates with possible changes in Tau in ALS patients based on ALS Functional Rating Scale (ALSFRS) scores.

Timeline

Start
2005-06
Primary completion
2009-07
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 10 mg